Assessing potential introduction of universal or targeted hepatitis A vaccination in the Netherlands

Vaccine

Volumn 30, Issue 35, 2012, Pages 5199-5205

  Suijkerbuijk, A W M ^a   Lugner A K ^a   van Pelt, W ^a   Wallinga, J ^a   Verhoef, L P B ^a   de Melker, H E ^a   de Wit, G A ^a,b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Burden; Costs; Elderly; Hepatitis A; Vaccination program

Indexed keywords

HEPATITIS A VACCINE;

ADULT; ANAPHYLAXIS; ARTICLE; BRAIN DISEASE; CHILD; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE TRANSMISSION; EPIDEMIC; FEVER; HEADACHE; HEALTH CARE COST; HEPATITIS A; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NETHERLANDS; PATHOGENICITY; PRIORITY JOURNAL; PRURITUS; RISK FACTOR; VACCINATION;

ADOLESCENT; ADULT; AGED; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HEPATITIS A; HEPATITIS A VACCINES; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MASS VACCINATION; MIDDLE AGED; NETHERLANDS; RISK FACTORS; YOUNG ADULT;

EID: 84863819449     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.014     Document Type: Article

References (50)

1. Jacobsen K.H., Koopman J.S. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect 2004, 132(December (6)):1005-1022.
2. Jacobsen K.H., Wiersma S.T. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010, 28(September (41)):6653-6657.
3. Beutels P., leyten J., Lejeune O., Hens N., Bilcke J., De Schrijver K. Evaluatie van universele en doelgroep hepatitis A vaccinatie opties in België 2008, Federaal Kenniscentrum voor de Gezondheidszorg (KCE), Brussel.
4. Verhoef L., Boot H.J., Koopmans M., Mollema L., Van Der Klis F., Reimerink J., et al. Changing risk profile of hepatitis A in The Netherlands: a comparison of seroprevalence in 1995-1996 and 2006-2007. Epidemiol Infect 2011, 139(August (8)):1172-1180.
5. Kimman T.G., Boot H.J., Berbers G.A., Vermeer-de Bondt P.E., Ardine de Wit G., de Melker H.E. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine 2006, 24(May (22)):4769-4778.
6. Boot H.J., de Melker H.E., Stolk E.A., de Wit G.A., Kimman T.G. Assessing the introduction of universal varicella vaccination in the Netherlands. Vaccine 2006, 24(September (37-39)):6288-6299.
7. van Lier A., van Hoek A.J., Opstelten W., Boot H.J., de Melker H.E. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res 2010, 10:237.
8. Zomer T.P., van Duynhoven Y.T., Mangen M.J., van der Maas N.A., Vennema H., Boot H., et al. Assessing the introduction of universal rotavirus vaccination in the Netherlands. Vaccine 2008, 26(July (29-30)):3757-3764.
9. Statistics_Netherlands [cited]. Available from: http://www.cbs.nl/.
10. Hakkaart-van Roijen L., Tan S.S., Bouwman C.A.M. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg 2011, College voor zorgverzekeringen, Diemen.
11. Dutch_Health_Authority [cited]. Available from: http://www.nza.nl/.
12. van Agthoven M., Metselaar H.J., Tilanus H.W., de Man R.A., IJzermans J.N., Martin van Ineveld B.M. A comparison of the costs and effects of liver transplantation for acute and for chronic liver failure. Transpl Int 2001, 14(2):87-94.
13. Havelaar A.T., Haagsma J.A., Mangen M.J.M., Kemmeren J.M., Verhoef L.P.B., Vijgen S.M.C., et al. Disease burden of foodborne pathogens in the Netherlands, 2009. Int J Food Microbiol 2012, 156(3):231-238.
14. Rahamat-Langendoen J.C., van Vliet J.A., Suijkerbuijk A.W. Recognition of threats caused by infectious diseases in the Netherlands: the early warning committee. Euro Surveill 2006, 11(12):242-245.
15. RIVM. Infectieziekten Bull [cited]. Available from: http://www.rivm.nl/infectieziektenbulletin.
16. Innis B.L., Snitbhan R., Kunasol P., Laorakpongse T., Poopatanakool W., Kozik C.A., et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994, 271(May (17)):1328-1334.
17. Vidor E., Fritzell B., Plotkin S. Clinical development of a new inactivated hepatitis A vaccine. Infection 1996, 24(November-December (6)):447-458.
18. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992, 327(August (7)):453-457.
19. Hepatitis A vaccines. Wkly Epidemiol Rec 2000, 75(February (5)):38-44.
20. Vidor E., Dumas R., Porteret V., Bailleux F., Veitch K. Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data. Eur J Clin Microbiol Infect Dis 2004, 23(April (4)):300-309.
21. WHO Hepatitis A 2010, World Health Organization, Geneva.
22. Victor J.C., Monto A.S., Surdina T.Y., Suleimenova S.Z., Vaughan G., Nainan O.V., et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007, 357(October (17)):1685-1694.
23. Zamir C., Rishpon S., Zamir D., Leventhal A., Rimon N., Ben-Porath E. Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine. Eur J Clin Microbiol Infect Dis 2001, 20(March (3)):185-187.
24. D'Acremont V., Herzog C., Genton B. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J Travel Med 2006, 13(March-April (2)):78-83.
25. Demicheli V., Tiberti D. The effectiveness and safety of hepatitis A vaccine: a systematic review. Vaccine 2003, 21(June (19-20)):2242-2245.
26. Niu M.T., Salive M., Krueger C., Ellenberg S.S. Two-year review of hepatitis A vaccine safety: data from the Vaccine Adverse Event Reporting System (VAERS). Clin Infect Dis 1998, 26(June (6)):1475-1476.
27. Fiore A.E., Wasley A., Bell B.P. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(May (RR-7)):1-23.
28. Hak E., Schonbeck Y., De Melker H., Van Essen G.A., Sanders E.A. Negative attitude of highly educated parents and health care workers towards future vaccinations in the Dutch childhood vaccination program. Vaccine 2005, 23(May (24)):3103-3107.
29. Paulussen T.G., Hoekstra F., Lanting C.I., Buijs G.B., Hirasing R.A. Determinants of Dutch parents' decisions to vaccinate their child. Vaccine 2006, 24(January (5)):644-651.
30. Koff R.S. Hepatitis A. Lancet 1998, 351(May (9116)):1643-1649.
31. Suijkerbuijk A.W., Lindeboom R., van Steenbergen J.E., Sonder G.J., Doorduyn Y. Effect of hepatitis A vaccination programs for migrant children on the incidence of hepatitis A in The Netherlands. Eur J Public Health 2009, 19(June (3)):240-244.
32. Kurugol Z., Aslan A., Turkoglu E., Koturoglu G. Changing epidemiology of hepatitis A infection in Izmir, Turkey. Vaccine 2011, 29(July (37)):6259-6261.
33. Kamal S.M., Mahmoud S., Hafez T., El-Fouly R. Viral hepatitis a to e in South Mediterranean countries. Mediterr J Hematol Infect Dis 2010, 21:e2010001.
34. Bouskraoui M., Bourrous M., Amine M. Prevalence of anti-hepatitis A virus antibodies in children in Marrakech. Arch Pediatr 2009, 16(October (Suppl. 2)):S132-S136.
35. Ratcliffe J., Young T., Longworth L., Buxton M. An assessment of the impact of informative dropout and nonresponse in measuring health-related quality of life using the EuroQol (EQ-5D) descriptive system. Value Health 2005, 8(January-February (1)):53-58.
36. Petrignani M., Verhoef L., van Hunen R., Swaan C., van Steenbergen J., Boxman I., et al. A possible foodborne outbreak of hepatitis A in the Netherlands, January-February 2010. Euro Surveill 2010, 15(March (11)).
37. O'Connor J.B., Imperiale T.F., Singer M.E. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults. Hepatology 1999, 30(October (4)):1077-1081.
38. Rajan E., Shattock A.G., Fielding J.F. Cost-effective analysis of hepatitis A prevention in Ireland. Am J Gastroenterol 2000, 95(January (1)):223-226.
39. Jacobs R.J., Greenberg D.P., Koff R.S., Saab S., Meyerhoff A.S. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J 2003, 22(October (10)):904-914.
40. Rein D.B., Hicks K.A., Wirth K.E., Billah K., Finelli L., Fiore A.E., et al. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics 2007, 119(January (1)):e12-e21.
41. Armstrong G.L., Billah K., Rein D.B., Hicks K.A., Wirth K.E., Bell B.P. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity. Pediatrics 2007, 119(January (1)):e22-e29.
42. Zhuang G.H., Pan X.J., Wang X.L. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China. Vaccine 2008, 26(August (35)):4608-4616.
43. Zahdi M.R., Maluf I., Maluf E.M. Hepatitis A: the costs and benefits of the disease prevention by vaccine, Parana, Brazil. Braz J Infect Dis 2009, 13(August (4)):257-261.
44. Valenzuela M.T., Jacobs R.J., Arteaga O., Navarrete M.S., Meyerhoff A.S., Innis B.L. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 2005, 23(July (32)):4110-4119.
45. Lopez E., Debbag R., Coudeville L., Baron-Papillon F., Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. J Gastroenterol 2007, 42(February (2)):152-160.
46. Ginsber G.M., Slater P.E., Shouval D. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol 2001, 34(January (1)):92-99.
47. European_Centre_for_Disease_Prevention_and_Control Annual epidemiological report 2011, ECDC, Stockholm.
48. Pechevis M., Khoshnood B., Buteau L., Durand I., Piquard Y., Lafuma A. Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection. Vaccine 2003, 21(September (25-26)):3556-3564.
49. Baaten G.G., Sonder G.J., Van Der Loeff M.F., Coutinho R.A., Van Den Hoek A. Fecal-orally transmitted diseases among travelers are decreasing due to better hygienic standards at travel destination. J Travel Med 2010, 17(September (5)):322-328.
50. Vacchino M.N. Incidence of hepatitis A in Argentina after vaccination. J Viral Hepat 2008, 15(October (Suppl. 2)):47-50.